GC Biopharma and Hanmi Seal Fabry Drug Deal
GC Biopharma and Hanmi Pharmaceutical signed an exclusive global licensing deal with BioMarin Pharmaceutical for LA-GLA, their jointly developed Fabry disease treatment candidate, valued at up to $475 million. The South Korean companies will receive $70 million upfront, may earn up to $405 million in milestone payments, and will receive royalties; they retain responsibility for South Korean approval and commercialization. BioMarin will lead development and commercialization elsewhere. Designed as a long-acting, self-administered subcutaneous enzyme replacement therapy, LA-GLA is in a global Phase 1/2 trial and received U.S. Orphan Drug Designation in 2024.
Style rédactionnelInformatif
Primarily factual business and drug-development reporting, with mildly positive characterizations of the partnership and candidate.